Quantcast

Latest Cancer treatments Stories

2014-06-03 11:48:40

University of Colorado Denver At the 50th Annual Meeting of the American Society for Clinical Oncology (ASCO), University of Colorado Cancer Center researchers reported results of a Phase I trial of OMP-54F28 (FZD8-Fc), an investigational drug candidate discovered by OncoMed Pharmaceuticals targeting cancer stem cells (CSCs). The drug was generally well tolerated, and several of the 26 patients with advanced solid tumors experienced stable disease for greater than six months. Three trials...

2014-06-02 08:30:18

SEATTLE, June 2, 2014 /PRNewswire/ - Oncothyreon Inc. (NASDAQ: ONTY) today announced the presentation of data from a Phase 1 trial of ONT-10, an antigen-specific immunotherapy targeting MUC1, at the American Association of Clinical Oncology (ASCO) 2014 Annual Meeting in Chicago. The data demonstrated that ONT-10 was well tolerated in this trial, resulted in a humoral immune response in the majority of patients and led to encouraging disease control in advanced stage patients with...

2014-06-01 08:20:43

New Study Shows Oncotype DX® DCIS Score(TM) Changes Treatment Recommendations for One Out of Three DCIS Patients REDWOOD CITY, Calif., June 1, 2014 /PRNewswire/ -- Genomic Health, Inc. (Nasdaq: GHDX) today announced results of six studies being presented at the 2014 American Society of Clinical Oncology(®) (ASCO(®)) Annual Meeting taking place May 30 - June 3 in Chicago, underscoring the practice-changing value of Oncotype DX(®)( )in pre-invasive and invasive breast cancer and colon...

2014-06-01 08:20:41

NEW YORK, June 1, 2014 /PRNewswire/ -- The Cancer Research Institute (CRI) is proud to announce the launch of a first-of-its-kind website devoted to cancer immunotherapy, also called immuno-oncology, designed specifically for cancer patients and their caregivers, TheAnswerToCancer.org. http://photos.prnewswire.com/prnvar/20140530/92827 "As major advances in cancer immunotherapy begin to alter the landscape of cancer treatment, patients facing a cancer diagnosis need to be aware of...

2014-05-31 08:21:17

Data Support Adoption of Stable Disease as Response Criterion, Raise Intriguing Hypotheses about Sequential Therapy and Utility of IL-2 as Salvage Option CHICAGO, May 31, 2014 /PRNewswire/ -- Prometheus Laboratories Inc. announced today that data from the PROCLAIM(SM) national patient registry retrospective cohort document an improvement in median overall survival (OS) in patients with metastatic melanoma who were treated with high-dose Proleukin(®) (aldesleukin) as compared to...

2014-05-30 08:25:14

Retrospective Analysis Demonstrates Survival Benefits for Patients with Stable and Progressive Disease after HD IL-2 in the Modern Era Suggesting Appropriate Drug Sequencing May Improve Outcomes CHICAGO, May 30, 2014 /PRNewswire/ -- Prometheus Laboratories Inc. announced today that analysis of data from the PROCLAIM(SM) national patient registry retrospective cohort shows improved overall survival in metastatic RCC patients treated with high-dose Proleukin(®) (aldesleukin) in the...

Miniature Artificial Lung In The Making
2014-05-29 16:07:40

Fraunhofer Institute for Interfacial Engineering and Biotechnology IGB What medications can be used to treat lung cancer, and how effective are they? Until now, drug companies have had to rely on animal testing to find out. But in the future, a new 3D model lung is set to achieve more precise results and ultimately minimize – or even completely replace – animal testing. From June 23-26, researchers will be presenting their new model at the BIO International Convention in San Diego,...

2014-05-29 12:29:19

PRINCETON, N.J., May 29, 2014 /PRNewswire/ -- inVentiv Health Clinical, a leading global clinical research organization (CRO), and Advaxis, Inc. (NASDAQ: ADXS), a biotechnology company developing cancer immunotherapies, announced today that they have entered into a global master services agreement for the clinical development of certain immunotherapy product candidates in Advaxis's proprietary pipeline. inVentiv initially will work with Advaxis to develop clinical study protocols and will...

2014-05-29 10:42:58

University of Texas M. D. Anderson Cancer Center Oncologists now have a new understanding of the toxicity levels of specific chemotherapy regimens used for women with early stage breast cancer, according to research from The University of Texas MD Anderson Cancer Center. The retrospective study, published in the Journal of Clinical Oncology, used large population-based data to compare the risk of hospitalization for six common chemotherapy regimens. Reasons for hospitalization included...

2014-05-28 16:26:44

-- Pediatric Patients Aged 1 Month to Less Than 17 Years Now Have A New Option to Help Prevent Acute Chemotherapy-Induced Nausea and Vomiting -- WOODCLIFF LAKE, N.J. and LUGANO, Switzerland, May 28, 2014 /PRNewswire/ -- Eisai Inc. and Helsinn Group today announced the Food and Drug Administration (FDA) approval of ALOXI(®) (palonosetron HCl) injection for the prevention of acute nausea and vomiting associated with initial and repeat courses of emetogenic cancer chemotherapy, including highly...


Word of the Day
penuche
  • A fudgelike confection of brown sugar, cream or milk, and chopped nuts.
'Penuche' is a variant of 'panocha,' a coarse grade of sugar made in Mexico. 'Panocha' probably comes from the Spanish 'panoja, panocha,' ear of grain.
Related